Welcome to chemicalbook!
Chinese English Japanese Germany Korea
+1 (818) 612-2111
18162-48-6872-50-4Methylene ChloridenaphthaleneTHFTitanium Dioxide
Structured search
Inquriy
Try our best to find the right business for you.
Messages
Do not miss inquiry messages Please log in to view all inquiry messages.
My chemicalbook My chemicalbook

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >API>Anesthetic Agents>Local anesthetics> Lidocaine hydrochloride
Lidocaine hydrochloride
  • Lidocaine hydrochloride
  • Lidocaine hydrochloride

Lidocaine hydrochloride NEW

Price $6 $5 $1
Package 1KG 25KG 100KG
Min. Order: 1KG
Supply Ability: g-kg-tons, free sample is available
Update Time: 2024-03-29

Product Details

Product Name: Lidocaine hydrochloride CAS No.: 73-78-9
Min. Order: 1KG Purity: 99%
Supply Ability: g-kg-tons, free sample is available Release date: 2024/03/29
Lead time: In stock Packaging: bottle/drum/bucket/IBC, as request.
Delivery: By sea, by air, by express Origin: Manufacturer
Name: Sun

1. Product information

 Names

Namelidocaine hydrochloride
SynonymMore Synonyms

 Lidocaine hydrochloride Biological Activity

DescriptionLidocaine Hcl salt, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.Target: Lidocaine is a common local anesthetic and antiarrhythmic drug. Lidocaine is used topically to relieve itching, burning and pain from skin inflammations, injected as a dental anesthetic or as a local anesthetic for minor surgery. Lidocaine, the first amino amide–type local anesthetic, was first synthesized under the name xylocaine by Swedish chemist Nils Lofgren in 1943. His colleague Bengt Lundqvist performed the first injection anesthesia experiments on himself.Lidocaine is approximately 95% metabolized (dealkylated) in the liver by CYP3A4 to the pharmacologically-active metabolites monoethylglycinexylidide (MEGX) and then subsequently to the inactive glycine xylidide. MEGX has a longer half life than lidocaine but also is a less potent sodium channel blocker. The elimination half-life of lidocaine is approximately 90–120 minutes in most patients. This may be prolonged in patients with hepatic impairment (average 343 minutes) or congestive heart failure (average 136 minutes).
Related Catalog
Signaling Pathways >> Membrane Transporter/Ion Channel >> Sodium Channel
Research Areas >> Inflammation/Immunology
References

[1]. VAN DER Wal S, et al. Lidocaine increases the anti-inflammatory cytokine IL-10 following mechanical ventilation in healthy mice. Acta Anaesthesiol Scand. 2014 Oct 14.

[2]. Acevedo-Arcique CM, et al. Lidocaine, dexmedetomidine and their combination reduce isoflurane minimum alveolar concentration in dogs. PLoS One. 2014 Sep 18;9(9):e106620.

 Chemical & Physical Properties

Boiling Point350.8ºC at 760 mmHg
Melting Point80-82°C
Molecular FormulaC14H23ClN2O
Molecular Weight270.798
Flash Point166ºC
Exact Mass270.149902
PSA32.34000
LogP3.45870
Storage conditionRefrigerator

 Toxicological Information

CHEMICAL IDENTIFICATION

  • RTECS NUMBER :

  • AN7600000

  • CHEMICAL NAME :

  • 2',6'-Acetoxylidide, 2-(diethylamino)-, hydrochloride

  • CAS REGISTRY NUMBER :

  • 73-78-9

  • LAST UPDATED :

  • 199712

  • DATA ITEMS CITED :

  • 27

  • MOLECULAR FORMULA :

  • C14-H22-N2-O.Cl-H

  • MOLECULAR WEIGHT :

  • 270.84

  • WISWESSER LINE NOTATION :

  • 2N2&1VMR B1 F1 &GH

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

  • TYPE OF TEST :

  • Standard Draize test

  • ROUTE OF EXPOSURE :

  • Administration onto the skin

  • SPECIES OBSERVED :

  • Rodent - rabbit

  • REFERENCE :

  • AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 137,410,1962

  • TYPE OF TEST :

  • Standard Draize test

  • ROUTE OF EXPOSURE :

  • Administration into the eye

  • SPECIES OBSERVED :

  • Rodent - rabbit

  • REFERENCE :

  • AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 137,410,1962 ** ACUTE TOXICITY DATA **

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - infant

  • DOSE/DURATION :

  • 1600 ug/kg/9H-I

  • TOXIC EFFECTS :

  • Behavioral - convulsions or effect on seizure threshold

  • REFERENCE :

  • AEMED3 Annals of Emergency Medicine. (American College of Emergency Physicians, 1125 Executive Circle, Irving, TX 75038) Volume(issue)/page/year: 17,725,1988

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human - infant

  • DOSE/DURATION :

  • 1632 mg/kg/1W-I

  • TOXIC EFFECTS :

  • Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold

  • REFERENCE :

  • CPEDAM Clinical Pediatrics (Philadelphia). (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1962- Volume(issue)/page/year: 22,190,1983

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Human - infant

  • DOSE/DURATION :

  • 10 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - convulsions or effect on seizure threshold Behavioral - coma Lungs, Thorax, or Respiration - other changes

  • REFERENCE :

  • JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 28,101,1990

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Human - child

  • DOSE/DURATION :

  • 60 mg/kg/1H

  • TOXIC EFFECTS :

  • Behavioral - convulsions or effect on seizure threshold Vascular - BP lowering not characterized in autonomic section

  • REFERENCE :

  • JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 24,51,1986

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Human - man

  • DOSE/DURATION :

  • 9 mg/kg/4H-C

  • TOXIC EFFECTS :

  • Cardiac - cardiomyopathy including infarction

  • REFERENCE :

  • DICPBB Drug Intelligence and Clinical Pharmacy. (POB 42435, Cincinnati, OH 45242) V.3- 1969- Volume(issue)/page/year: 19,669,1985

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Human - man

  • DOSE/DURATION :

  • 7143 ug/kg

  • TOXIC EFFECTS :

  • Cardiac - pulse rate increase, without fall in BP

  • REFERENCE :

  • CHETBF Chest. (American College of Chest Physicians, 911 Busse Hwy, Park Ridge, IL 60068) V.57- 1970- Volume(issue)/page/year: 61,682,1972

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Implant

  • SPECIES OBSERVED :

  • Human - man

  • DOSE/DURATION :

  • 5714 ug/kg

  • TOXIC EFFECTS :

  • Behavioral - convulsions or effect on seizure threshold

  • REFERENCE :

  • CMAJAX Canadian Medical Association Journal. (Canadian Medical Assoc., POB 8650, Ottawa, ON K1G 0G8, Canada) V.1- 1911- Volume(issue)/page/year: 137,219,1987

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 122 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 111,224,1954

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 570 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • RPOBAR Research Progress in Organic-Biological and Medicinal Chemistry. (New York, NY) V.1-3, 1964-72. Discontinued. Volume(issue)/page/year: 2,299,1970

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 21 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • RPOBAR Research Progress in Organic-Biological and Medicinal Chemistry. (New York, NY) V.1-3, 1964-72. Discontinued. Volume(issue)/page/year: 2,299,1970

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 220 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • RPOBAR Research Progress in Organic-Biological and Medicinal Chemistry. (New York, NY) V.1-3, 1964-72. Discontinued. Volume(issue)/page/year: 2,299,1970

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 63 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 274,253,1985

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 163 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • PSEBAA Proceedings of the Society for Experimental Biology and Medicine. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1903/04- Volume(issue)/page/year: 103,353,1960

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 15 mg/kg

  • TOXIC EFFECTS :

  • Behavioral - altered sleep time (including change in righting reflex) Lungs, Thorax, or Respiration - respiratory stimulation

  • REFERENCE :

  • JPPMAB Journal of Pharmacy and Pharmacology. (Pharmaceutical Soc. of Great Britain, 1 Lambeth High St., London SEI 7JN, UK) V.1- 1949- Volume(issue)/page/year: 14,48T,1962

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intramuscular

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 177 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • DDREDK Drug Development Research. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1981- Volume(issue)/page/year: 21,277,1990

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Mammal - dog

  • DOSE/DURATION :

  • 65700 ug/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • JNPHAG Journal de Pharmacologie. (SPPIF, B.P.22, F-41353 Vineuil, France) V.1- 1970- Volume(issue)/page/year: 2,240,1971

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Rodent - rabbit

  • DOSE/DURATION :

  • 25600 ug/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,879,1982

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intratracheal

  • SPECIES OBSERVED :

  • Rodent - rabbit

  • DOSE/DURATION :

  • 28 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 200,359,1972

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Rodent - guinea pig

  • DOSE/DURATION :

  • 24500 ug/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 113,313,1958

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Parenteral

  • SPECIES OBSERVED :

  • Amphibian - frog

  • DOSE/DURATION :

  • 159 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • REFERENCE :

  • AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 289,278,1987 ** REPRODUCTIVE DATA **

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Implant

  • DOSE :

  • 7500 mg/kg

  • SEX/DURATION :

  • female 3-17 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Maternal Effects - parturition Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • REFERENCE :

  • ANESAV Anesthesiology. (Lippincott/Harper, Journal Fulfillment Dept., 2350 Virginia Ave., Hagerstown, MD 21740) V.1- 1940- Volume(issue)/page/year: 65,626,1986 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 83491 No. of Facilities: 397 (estimated) No. of Industries: 3 No. of Occupations: 5 No. of Employees: 13412 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 83491 No. of Facilities: 1385 (estimated) No. of Industries: 6 No. of Occupations: 17 No. of Employees: 68071 (estimated) No. of Female Employees: 56919 (estimated)

 Safety Information

RIDADR3249
Packaging GroupIII
Hazard Class6.1(b)
HS Code2924299090

 Precursor & DownStream

Precursor  0



DownStream  2



  • Article illustration CAS#:7728-40-7
    Monoethylglycin...

  • Article illustration CAS#:32845-42-4
    3-(2,6-dimethyl...

 Customs

HS Code2924299090
Summary2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

 Synonyms

LIDOCAINE HCL
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide,hydrochloride
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamidhydrochlorid
Xyloneural
XYLOCAINE HYDROCHLORIDE
N-(2,6-Dimethylphenyl)-N,N-diethylglycinamide hydrochloride (1:1)
MFCD00034865
(Diethylamino)-2',6'-acetoxylidide Monohydrochloride
2-(diéthylamino)-N-(2,6-diméthylphényl)acétamide chlorhydrate
Xilina hydrochloride
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide, hydrochloride (1:1)
N-(2,6-dimethylphenyl)-N,N-diethylglycinamide hydrochloride
Lidocaine hydrochloride
lignocaine hydrochloride
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide monohydrochloride
Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, hydrochloride (1:1)
Lidocaton
Lidothesin
Laryng-O-jet
N-(2,6-dimethylphenyl)-N2,N2-diethylglycinamide hydrochloride
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrochloride
EINECS 200-803-8
2',6'-Acetoxylidide, 2-(diethylamino)-, monohydrochloride (8CI)
Xylocard
2N2&1VMR B1 F1 &&HCl
Lidocaine (hydrochloride)


2. Packaging

For powders: normal is 25kgs/Drum or bag, or larger/smaller package as request.

For liquids: normal 25kgs/drum, 180-300kgs/bucket, or IBC, determined by the nature of the product. 

                     Or smaller package 1kg/bottle, 10kgs/bottle as request. 


Article illustrationArticle illustration


3. Shipping

Article illustration


4. Contact information

For more details, pls contact us freely.

Email address : Sun@fdachem.com

Mob: 86 13526505137

WhatsApp/Skype/Wechat/LINE: 86 13526505137





Company Profile Introduction

Henan Fengda Chemical Co., Ltd. is located in the High-tech Development Zone of Henan Province. Specializing in the production and sales of various fine chemical products required for industrial production, including chemical raw materials, organic raw materials, petrochemicals, chemical reagents, solvents, catalysts, and additives, etc.

You may like

Recommended supplier

Product name Price   Suppliers Update time
Lidocaine HCL
 $10.00/1kg
VIP1Y
Hebei Ganmiao New material Technology Co., LTD
 2024-06-07
Lidocaine hydrochloride
 $6.00/1KG
VIP1Y
Hebei Saisier Technology Co., LTD
 2024-06-04
Lidocaine hydrochloride
 $10.00/1kg
VIP1Y
Nanjing Deda New Material Technology Ltd.
 2024-06-04
Lidocaine hydrochloride
 $1.00/1g
VIP1Y
Apeloa production Co.,Limited
 2024-05-24
Lidocaine hydrochloride
 $23.00/1kg
VIP6Y
Wuhan Boyuan Import & Export Co., LTD
 2024-05-23
Lidocaine Impurity 2
 $0.00/10mg
VIP1Y
ShenZhen H&D Pharmaceutical Technology Co., LTD
 2024-05-21
Lidocaine hydrochloride
 $0.00/25kg
VIP1Y
Hebei Mojin Biotechnology Co.,Ltd
 2024-05-17
Lidocaine hcl
 $20.00/25kg
VIP1Y
Ouhuang Engineering Materials (Hubei) Co., Ltd
 2024-04-15
Lidocaine hydrochloride
 $20.00/1kg
VIP1Y
Shaanxi Franta Biotechnology Co., Ltd
 2024-03-27
Lidocaine hydrochloride
 $20.00/1kg
VIP1Y
Hebei Kangcang new material Technology Co., LTD
 2024-03-27

Henan Fengda Chemical Co., Ltd

1YR ChinaChina
webchat
  • Since: 2023-02-10
  • Address: Room 01, 2288 E05, Building 14, East Henan University, Science and Technology Park, 279 Xisanhuan Ro
INQUIRY